Endocrine abnormality in paraneoplastic syndrome

Michael C Onyema, Georgios K Dimitriadis, Eftychia E Drakou

Research output: Contribution to journalReview articlepeer-review

Abstract

Paraneoplastic syndromes denote rare but notable phenomena caused by the tumour mediated release of bioactive substances. Peptide and non-peptide hormone causes are explored with a particular focus on pathogenesis, symptoms, diagnosis and treatment. Early detection and management of paraneoplastic syndromes can improve morbidly and mortality; definitive treatment remains effective surgical or anti-tumour therapies. Pituitary autoimmunity may provide a novel presentation of paraneoplastic syndromes for which further research is warranted.
Original languageEnglish
JournalBest Practice & Research: Clinical Endocrinology & Metabolism
Publication statusAccepted/In press - 20 Jan 2022

Fingerprint

Dive into the research topics of 'Endocrine abnormality in paraneoplastic syndrome'. Together they form a unique fingerprint.

Cite this